oncology clinical trials successful design conduct and analysis
Oncology Clinical Trials: Successful Design, Conduct, and Analysis
$113.00 Original price was: $113.00.$4.99Current price is: $4.99. Add to cart
Sale!

Oncology Clinical Trials: Successful Design, Conduct, and Analysis

Original price was: $113.00.Current price is: $4.99.

-96%

Flash Sale: Any ebook for just 4.99 USD only

  • Pay with Any Debit/Credit Card
  • Affordable Prices for Readers
Guaranteed Safe Checkout

The Architecture of the Cure: Oncology Clinical Trials

The entire edifice of modern cancer treatment is built on the brutal, unforgiving mathematics of the clinical trial. You cannot legally claim a new drug cures cancer unless you have mathematically proven it against the established standard of care. Oncology Clinical Trials: Successful Design, Conduct, and Analysis is the fiercely precise, absolutely non-negotiable biostatistical manual detailing exactly how to build these experiments. This volume provides the exact regulatory and mathematical blueprints required to legally prove a drug’s efficacy.

Mastering the Phase I Dose Escalation

The core philosophy of this text is the calculated risk of toxicity. The authors aggressively detail the mechanics of the first-in-human trial. It dictates exactly how a researcher must use the “3+3 design” to carefully increase the dose of a brand-new, highly toxic chemical in terminal patients, specifically searching for the Maximum Tolerated Dose (MTD) before the drug causes lethal organ failure.

Navigating the Survival Endpoint

The book provides a masterclass in statistical significance. It dictates the exact computational pathways for the Phase III trial. It rigorously explores the maddening complexity of the Kaplan-Meier survival curve, detailing how bio-statisticians mathematically prove that a new drug extending a patient’s life by exactly 2.4 months is a statistically significant breakthrough worthy of FDA approval and billions of dollars.

Frequently Asked Questions (FAQs)

Does this book provide the chemotherapy dosing for standard patient care?
No, it is a strictly specialized *biostatistics, clinical research, and regulatory affairs textbook* focused entirely on the mathematical design and legal execution of human experiments.

Who is the primary audience?
It is the absolute, mandatory benchtop reference for Clinical Trial Investigators, Bio-statisticians, Pharmaceutical Researchers, and Oncology Fellows.